Jounce Therapeutics has emerged from its quiet period with $47 million in initial funding. The biotech startup from Third Rock Ventures seeks to develop injectable protein drugs including antibodies as therapies for cancer.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||